IP Library Granted Patent US 9,278,093
Granted Patent B2
US 9,278,093 · App. 14/389,172 · Granted Mar 8, 2016

Aldosterone synthase inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,278,093
App. No.
14/389,172
Granted
Mar 8, 2016
Kind
B2
Abstract

This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

Claims (15)

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 which is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 which is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 which is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 which is

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound as defined in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of at least one additional therapuetic agent and a pharmaceutically acceptable carrier.

8. A method for the treatment or amelioration of one or more of the conditions associated with inhibiting CYP11B2, which comprises administering therapeutically effective amount of at least one compound as defined in claim 1 or a pharmaceutically acceptable salt thereof to mammal in need of such treatment, wherein the conditions that could be treated or ameliorated by inhibiting CYP11B2 are hypertension, left ventricular diastolic dysfunction, renal failure, retinopathy.

9. A method for inhibiting CYP11B2 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof.

Assignments (6)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2015
From: BEY, EMMANUEL
To: ELEXOPHARM GMBH
Reel/Frame 035177/0844 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2015
From: ALI, AMJAD
To: MERCK SHARP & DOHME CORP.
Reel/Frame 035178/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2015
From: UNIVERSITAET DES SAARLANDES
To: ELEXOPHARM GMBH
Reel/Frame 035178/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2015
From: HARTMANN, ROLF; HU, QINGZHONG
To: UNIVERSITAET DES SAARLANDES
Reel/Frame 035178/0358 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2015
From: YIN, LINA
To: ELEXOPHARM GMBH
Reel/Frame 035178/0464 →